Unopposed noncontraceptive estrogen therapy slightly increases the risk of endometrial cancer
un·op·posed -ə-ˈpōzd : being or relating to estrogen replacement therapy in which a progestin (as medroxyprogesterone acetate) is not coadministered to reduce the potential risks (as endometrial cancer) associated with estrogen used alone Last...
Malignancy arising in endometriosis associated with unopposed estrogen replacement. Risk of endometrial cancer in relation to use of Low-Dose, unopposed estrogens ** Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating a... ...
aA patient undergoing unopposed estrogen therapy with endometrial thickening exceeding 8 mm should be considered for biopsy, whereas patients receiving progesterone in addition to estrogen can be rescanned at the beginning or end of the following cycle to determine if there has been a change in ...
Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study. To examine the relation of noncontraceptive estrogen use to the risk of breast cancer among postmenopausal women, the authors conducted a case-control stud... DW Kaufman,JR Palmer,Mouzon ...
medical being or relating to estrogen replacement therapy in which a progestin (such as medroxyprogesterone acetate) is not coadministered to reduce the potential risks (such as endometrial cancer) associated with estrogen used alone A woman who has had her uterus removed can take the estrogen "un...
We found that estrogen-induced risk of endometrial cancer decreases rapidly as the estrogen-free interval increases. The RR estimates, adjusted for duration of use and potential confounding factors, declined from 5.0 for those receiving their latest prescription within 24 months (95 percent confidence ...
OBJECTIVE To determine if use of a low dose of unopposed conjugated estrogen (0.3 mg/day) is associated with an increased risk of endometrial cancer in middle-aged women. DESIGN Case-control study. SETTING Population based study in the USA. PATIENTS Cases aged 45-74 years, diagnosed with ...
Unopposed estrogen increases endometrial hyperplasia riskInpharma Weekly -doi:10.2165/00128413-199610250-00046NoneSpringer International PublishingInpharma Weekly
The increasing number of HRT prescriptions, time pressures in primary care and the known risk from using unopposed estrogen of endometrial cancer means these changes are of potential great value.Horrocks, LizHolloway, DebraRymer, JaniceBruce, Deborah...